Texas SB2674 mandates health benefit plans to cover biomarker testing for diagnosis, treatment, and management of diseases.

SB2674 amends the Texas Insurance Code to require health benefit plans to cover biomarker testing for diagnosis, treatment, management, or monitoring of an enrollee's disease or condition. This coverage applies when the test is supported by evidence such as FDA approval, Medicare determinations, clinical guidelines, or consensus statements. The law takes effect September 1, 2025, and applies to plans delivered, issued, or renewed after January 1, 2026.

Texas SB2674 mandates health benefit plans to cover biomarker testing for diagnosis, treatment, and management of diseases.

SB2674 amends the Texas Insurance Code to require health benefit plans to cover biomarker testing for diagnosis, treatment, management, or monitoring of an enrollee's disease or condition. This coverage applies when the test is supported by evidence such as FDA approval, Medicare determinations, clinical guidelines, or consensus statements. The law takes effect September 1, 2025, and applies to plans delivered, issued, or renewed after January 1, 2026.